Risk stratification of patients with SARS-CoV-2 by tissue factor expression in circulating extracellular vesicles.
CD142
COVID-19
Extracellular vesicles
SARS-CoV2
Tissue factor
Journal
Vascular pharmacology
ISSN: 1879-3649
Titre abrégé: Vascul Pharmacol
Pays: United States
ID NLM: 101130615
Informations de publication
Date de publication:
08 2022
08 2022
Historique:
received:
19
03
2022
revised:
15
04
2022
accepted:
13
05
2022
pubmed:
22
5
2022
medline:
21
9
2022
entrez:
21
5
2022
Statut:
ppublish
Résumé
Inflammatory response following SARS-CoV-2 infection results in substantial increase of amounts of intravascular pro-coagulant extracellular vesicles (EVs) expressing tissue factor (CD142) on their surface. CD142-EV turned out to be useful as diagnostic biomarker in COVID-19 patients. Here we aimed at studying the prognostic capacity of CD142-EV in SARS-CoV-2 infection. Expression of CD142-EV was evaluated in 261 subjects admitted to hospital for pneumonia and with a positive molecular test for SARS-CoV-2. The study population consisted of a discovery cohort of selected patients (n = 60) and an independent validation cohort including unselected consecutive enrolled patients (n = 201). CD142-EV levels were correlated with post-hospitalization course of the disease and compared to the clinically available 4C Mortality Score as referral. CD142-EV showed a reliable performance to predict patient prognosis in the discovery cohort (AUC = 0.906) with an accuracy of 81.7%, that was confirmed in the validation cohort (AUC = 0.736). Kaplan-Meier curves highlighted a high discrimination power in unselected subjects with CD142-EV being able to stratify the majority of patients according to their prognosis. We obtained a comparable accuracy, being not inferior in terms of prediction of patients' prognosis and risk of mortality, with 4C Mortality Score. The expression of surface vesicular CD142 and its reliability as prognostic marker was technically validated using different immunocapture strategies and assays. The detection of CD142 on EV surface gains considerable interest as risk stratification tool to support clinical decision making in COVID-19.
Identifiants
pubmed: 35597450
pii: S1537-1891(22)00048-9
doi: 10.1016/j.vph.2022.106999
pmc: PMC9116046
pii:
doi:
Substances chimiques
Biomarkers
0
Thromboplastin
9035-58-9
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
106999Informations de copyright
Copyright © 2022 Elsevier Inc. All rights reserved.
Déclaration de conflit d'intérêts
Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
Références
Arterioscler Thromb Vasc Biol. 2021 Feb;41(2):878-882
pubmed: 33267656
J Extracell Vesicles. 2021 Jul;10(9):e12117
pubmed: 34262673
Neurology. 2021 Feb 9;96(6):e937-e946
pubmed: 33184230
Curr Med Chem. 2020;27(27):4440-4468
pubmed: 31838988
Hypertension. 2021 Sep;78(3):726-737
pubmed: 34304584
EBioMedicine. 2021 May;67:103369
pubmed: 33971404
Blood Adv. 2021 Feb 9;5(3):628-634
pubmed: 33560376
JACC Basic Transl Sci. 2021 Mar;6(3):202-218
pubmed: 33649738
J Heart Lung Transplant. 2020 Oct;39(10):1136-1148
pubmed: 32665078
Transl Res. 2022 Jun;244:114-125
pubmed: 35202881
Blood. 2021 Jul 29;138(4):344-349
pubmed: 34075401
J Extracell Vesicles. 2013 May 27;2:
pubmed: 24009894
Stroke. 2021 Oct;52(10):3335-3347
pubmed: 34344167
BMJ. 2020 Sep 9;370:m3339
pubmed: 32907855
J Extracell Vesicles. 2020 Apr 17;9(1):1751428
pubmed: 32363015
Neurol Neuroimmunol Neuroinflamm. 2020 Aug 12;7(6):
pubmed: 32817412
Sci Rep. 2016 Nov 17;6:37246
pubmed: 27853258
J Extracell Vesicles. 2021 Jun;10(8):e12092
pubmed: 34122778
Arterioscler Thromb Vasc Biol. 2021 Jun;41(6):e379-e380
pubmed: 34038167
J Chronic Dis. 1987;40(5):373-83
pubmed: 3558716
Arterioscler Thromb Vasc Biol. 2021 Jun;41(6):e381-e382
pubmed: 34038165
BMJ. 2020 Apr 7;369:m1328
pubmed: 32265220
Intensive Care Med. 2020 May;46(5):833-836
pubmed: 32125458
Front Immunol. 2018 Jun 13;9:1326
pubmed: 29951064
J Extracell Vesicles. 2016 Feb 19;5:29975
pubmed: 26901056
Eur Respir J. 2020 Dec 24;56(6):
pubmed: 32978307
J Am Coll Cardiol. 2020 Jun 9;75(22):2819-2832
pubmed: 32498810
Signal Transduct Target Ther. 2021 Jul 7;6(1):255
pubmed: 34234112
Geroscience. 2020 Aug;42(4):1021-1049
pubmed: 32430627
Biomedicines. 2021 Feb 25;9(3):
pubmed: 33669043
J Cell Mol Med. 2020 Sep;24(17):9945-9957
pubmed: 32666618
Thromb Haemost. 2016 Jul 4;116(1):103-14
pubmed: 27052787
Heart Fail Rev. 2021 Mar;26(2):371-380
pubmed: 32844337
Pharmacol Res. 2021 Jun;168:105581
pubmed: 33781873
Thromb Res. 2012 May;129 Suppl 2:S13-7
pubmed: 22398016
Lancet Respir Med. 2020 May;8(5):475-481
pubmed: 32105632